Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1
Open Label Trial of Ranolazine in Myotonia Congenita, Paramyotonia Congenita, & Myotonic Dystrophy Type 1
Sponsor: Gilead Sciences
Listed as NCT02251457, this PHASE1 trial focuses on Myotonia Congenita and Myotonic Dystrophy 1 and remains completed. Sponsored by Gilead Sciences, it has been updated 9 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE1
Phase: PHASE2 → PHASE1
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Apr 2017 — Mar 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
- Ohio State University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Columbus, United States